Navigation Links
GSK Notice of First Quarter 2009 Financial Results Announcement and Teleconference
Date:4/21/2009

PHILADELPHIA, April 21 /PRNewswire-FirstCall/ -- On Wednesday, April 22, 2009 GlaxoSmithKline plc (NYSE: GSK) will announce its first quarter financial results for the three months ended March 31, 2009. It is anticipated that the announcement will be released to the London Stock Exchange at approximately 7:00 AM EDT.

At 8:30 AM EDT Andrew Witty, Chief Executive Officer, and Julian Heslop, Chief Financial Officer will hold a briefing meeting for analysts and investors. A webcast will begin at the same time as the teleconference and can be accessed directly at www.gsk.com.

To listen in to the live presentation and Q&A session by phone please dial:

          U.S. toll free phone:    1 866 804 8688
          U.S. toll:               1 718 354 1175

          Passcode:                GSK Q1 Results

An archived version of this webcast will be available from the GSK website at approximately 2:00 PM EDT on the same day.


'/>"/>
SOURCE GlaxoSmithKline plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Vermillion, Inc. Announces Receipt of Notice of Noncompliance From Nasdaq
2. Mediware Information Systems, Inc. Receives Notice from the Nasdaq Stock Market
3. Summary Notice of Class Action in Re McKesson HBOC, Inc. Securities Litigation
4. Innocoll Receives Intends to Grant Notices from the European Patent Office for Two European Patent Applications Related to Novel Wound Healing, Biosurgery and Drug Delivery Applications of its CollaRx(R) Technology
5. ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent
6. Medifast Receives Notice Regarding NYSE Listing
7. Melanomas may appear noticeably different than other moles
8. Putting the Medical Profession on Notice!: Widow Tells Tragic Story of How Her Husband Died Due to Misdiagnosis and Mistreatment
9. Summary Notice of Proposed Settlement and Settlement Hearing in Re Martek Biosciences Corp., Securities Litigation
10. GenOdyssee Receives Notice of Allowance from U.S. Patent Office for Improved Interferon-Alpha Aimed at Hepatitis C
11. Politics has taken notice of science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Boca Raton, FL (PRWEB) , ... January 20, 2017 , ... ... combining seaweeds, botanicals and 100 percent pure essential oils, announced the company had a ... Head, SC. , The annual ECRM event gives companies that work in the nutritional, ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... International Protein, ... nutritional and bodybuilding supplements, announced it attended the January ECRM trade show in Hilton ... and nutritional scientist who was determined to create a line of products that would ...
(Date:1/20/2017)... ... ... Angel”: a heartwarming and earnest tale of faith and believing in the path ... the creation of published author, Marjorie Lund-Fontaine, a former professional violinist, alumnus of The ... of her new book, Marjorie says, “‘The Angel’ was written as a fairytale, but ...
(Date:1/20/2017)... ... 2017 , ... “Journey to Christmas:” a beautiful and enchanting tale that teaches children the true ... mother of three in Oklahoma City, and a devoted woman of faith. , “Becoming ... been in the back of my mind for years, but actually doing it might have ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Management System: an On-demand E-learning system for Clinical and Regulatory education for ... is based on Aerolib`s successful education methodology of Disease Specific Documentation Improvement. ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Jan. 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ... mitochondrial dysfunction, today announced new additions to its senior ... Chief Medical Officer, and Daniel Geffken as ... Jim Carr , Pharm.D. has been promoted to ... pleased to welcome Doug and Daniel to our management ...
(Date:1/19/2017)... CITY, Calif. , Jan. 19, 2017  Abaxis, ... company manufacturing point-of-care blood analysis instruments and consumables for ... conference call to discuss its financial results for the ... The call will be at 4:15 p.m. ET on ... results for the third quarter fiscal year 2017 after ...
(Date:1/19/2017)... LEXINGTON, Massachusetts , January 19, 2017 ... SHPG ) announced that the U.S. Food and Drug ... resubmission of a New Drug Application (NDA) for SHP465, ... being evaluated as a potential once-daily treatment for Attention-Deficit/Hyperactivity ... decision on or around June 20, 2017, the designated ...
Breaking Medicine Technology: